Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.54 |
| ▸ | JAK2 | O60674 | 12/20 | 0.54 |
| ▸ | JAK1 | P23458 | 8/20 | 0.54 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12296758 | 0.85 | JAK3 (0.62) | JAK3JAK2JAK1MAPK1 | |
| SCHEMBL2376301 | 0.84 | JAK2 (0.58) | JAK3JAK2JAK1MAPK1 | |
| SCHEMBL2379317 | 0.82 | JAK2 (0.51) | JAK3JAK2JAK1ALDH1A1 | |
| SCHEMBL27838160 | 0.80 | CDK8 (0.54) | JAK3JAK2JAK1MAPK1 | |
| SCHEMBL2377622 | 0.78 | JAK2 (0.54) | JAK3JAK2JAK1MAPK1 | |
| SCHEMBL12245475 | 0.77 | KDM4E (0.59) | JAK3JAK2JAK1MAPK1 | |
| SCHEMBL2378448 | 0.76 | JAK3 (0.58) | JAK3JAK2JAK1MAPK1ALDH1A1 | |
| SCHEMBL2377302 | 0.76 | JAK3 (0.62) | JAK3JAK2JAK1MAPK1 | |
| SCHEMBL2378478 | 0.76 | JAK2 (0.52) | JAK3JAK2JAK1PRMT3MAPK1 | |
| SCHEMBL12970653 | 0.75 | JAK3 (0.59) | JAK3JAK2JAK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | claimed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | claimed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | JAK3 2/4885JAK2 5/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.